Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 21, 2008 - Issue 3
Submit an article Journal homepage
462
Views
121
CrossRef citations to date
0
Altmetric
Articles

Hepatocellular Carcinoma: Management of an Increasingly Common Problem

Gary L. DavisCorrespondence[email protected]
, MD,
Jane Dempster
, RN,
James D. Meler
, MD,
Douglas W. Orr
, MD,
Mark W. Walberg
, MD,
Brian Brown
, APRN,
Brian D. Berger
, MD,
John K. O'Connor
, MD &
Robert M. Goldstein
, MD show all
Pages 266-280 | Published online: 11 Dec 2017

  • World Health Organization. Mortality Database, WHO Statistical Information System. Available at http://www.who.int/whosis/en/; accessed March 19, 2008.
  • Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127 (5 Suppl 1): S5–S16.
  • US Mortality Public Use Data Tables, 1969–2004, National Center for Health Statistics, Centers for Disease Control and Prevention. 2006. Available at http://www.cancer.org/docroot/STT/stt_0.asp; accessed March 19, 2008.
  • Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK, eds. SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute, 2006. Available at http://seer.cancer.gov/csr/1975_2003/; accessed March 19, 2008.
  • King H, Locke FB. Cancer mortality among Chinese in the United States. J Natl Cancer Inst 1980;65 (5): 1141–1148.
  • Rosenblatt KA, Weiss NS, Schwartz SM. Liver cancer in Asian migrants to the United States and their descendants. Cancer Causes Control 1996;7 (3): 345–350.
  • El-Serag H. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127 (5 Suppl 1): S27–S34.
  • Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9 (4): 331–338.
  • Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90 (10): 1562–1569.
  • Simonetti RS, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36 (7): 962–972.
  • Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Valla D, Belghiti J, Degott C, Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32 (2): 200–204.
  • Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. J Hepatol 1999;31 (3): 508–513.
  • Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43 (6): 1303–1310.
  • Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21 (3): 650–655.
  • Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M; Inhibition of Hepatocarcinogenesis by Interferon Therapy (IHIT) Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131 (3): 174–181.
  • Fattovich F, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127 (5 Suppl 1): S35–S50.
  • Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW; European Concerted Action on Viral Hepatitis (EUROHEP). Long-term outcome of hepatitis Be antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997;26 (5): 1338–1342.
  • Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351 (15): 1521–1531.
  • Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317 (5834): 121–124.
  • Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E; European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97 (11): 2886–2895.
  • Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986;90 (2): 263–267.
  • Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007;26 (9): 1187–1194.
  • Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145 (11): 1039–1047.
  • Chen CH, Chen YY, Chen GH, Yang SS, Tang HS, Lin HH, Lin DY, Lo SK, Du JM, Chang TT, Chen SC, Liao LY, Kuo CH, Lin KC, Tai DI, Changchien CS, Chang WY, Sheu JC, Chen DS, Liaw YF, Sung JL. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol 2004;40 (4): 653–659.
  • Lugassy C, Bernuau J, Thiers V, Krosgaard K, Degott C, Wantzin P, Schalm SW, Rueff B, Benhamou JP, Tiollais P, et al Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987;155 (1): 64–71.
  • Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127 (5 Suppl 1): S56–S61.
  • Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98 (9): 2060–2063.
  • Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127 (5 Suppl 1): S17–S26.
  • Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332 (22): 1463–1466.
  • Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47 (1): 131–136.
  • Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112 (2): 463–472.
  • Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45 (3): 579–587.
  • Lai MM, Ware CF. Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr Top Microbiol Immunol 2000;242: 117–134.
  • Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285 (5424): 107–110.
  • Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300 (5622): 1145–1148.
  • National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, US Department of Health and Human Services. Behavioral Risk Factors Surveillance System (BRFSS). CD-ROM 1984–1995 (Series 1, No. 1, 2nd ed.), 1996–1997 (Series 1, No. 2a, Series 1, No. 3), 1998 (Series 1, No. 4), 1999 (Series 1, No. 5); 2000–2004. Available at http://www.cdc.gov/brfss/; accessed March 19, 2008.
  • Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend 2004;74 (3): 223–234.
  • Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P, Nardi G; Brescia HCC Study. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Hepatology 1997;26 (3): 579–584.
  • Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155 (4): 323–331.
  • Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, Gelatti U, Bucella E, Tomasi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000;9 (2): 213–216.
  • Miyakawa H, Sato C, Tazawa J, Izumi N, Hattori K, Ebata A, Maeda M, Ikeda T, Hirata R, Mae S, et al A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Alcohol Alcohol Suppl 1994;29 (1): 75–79.
  • Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S87–S96.
  • Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, et al Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328 (25): 1797–1801.
  • Fukushima W, Tanaka T, Ohfuji S, Habu D, Tamori A, Kawada N, Sakaguchi H, Takeda T, Nishiguchi S, Seki S, Shiomi S, Hirota Y. Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? Hepatol Res 2006;34 (3): 141–149.
  • Delarocque-Astagneau E, Roudot-Thoraval F, Campèse C, Desenclos JC, The Hepatitis C Surveillance System Steering Committee. Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001. Ann Epidemiol 2005;15 (8): 551–557.
  • Simonetti RG, Cammà C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxì A, Ciccaglione A, Giuseppetti R, et al Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992;116 (2): 97–102.
  • Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28 (6): 930–938.
  • Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36 (5): 1206–1213.
  • Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89 (1): 53–59.
  • Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28 (6): 1687–1695.
  • Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D; Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997;26 (2): 485–490.
  • Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27 (4): 914–919.
  • Stroffolini T, Sagnelli E, Mariano A, Craxí A, Almasio P; Italian Hospitals Collaborating Group. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. J Viral Hepat 2006;13 (5): 351–354.
  • Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28 (6): 1687–1695.
  • Donato F, Gelatti U, Chiesa R, Albertini A, Bucella E, Boffetta P, Tagger A, Ribero ML, Portera G, Fasola M, Nardi G; Brescia HCC Study. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Cancer Causes Control 1999;10 (5): 417–421.
  • Ohishi W, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, Kamiyasu M, Nakanishi T, Tazuma S, Chayama K. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003;38 (8): 894–900.
  • Noda K, Yoshihara H, Suzuki K, Yamada Y, Kasahara A, Hayashi N, Fusamoto H, Kamada T. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996;20 (1 Suppl): 95A–100A.
  • Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, Halliday JW, Bassett ML, Powell LW. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75 (1): 81–84.
  • Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313 (20): 1256–1262.
  • Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15 (4): 655–659.
  • Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S79–S86.
  • Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29 (3): 664–669.
  • Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36 (6): 1349–1354.
  • El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4 (3): 369–380.
  • Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35 (6): 1485–1493.
  • Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38 (2): 420–427.
  • Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44 (4): 865–873.
  • Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997;27 (2): 320–330.
  • La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer. A review of the evidence. Drug Saf 1996;14 (4): 260–272.
  • Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25 (27): 3787–3800.
  • Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6 (9): 674–687.
  • Chiang DY, Villanueva A, Hoshida Y, et al A novel molecular classification of HCV-related hepatocellular carcinoma based on integrative genomic analysis [abstract]. Presented at the 43rd meeting of the European Association for the Study of the Liver, Milan, Italy, April 24, 2008.
  • Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87 (2): 159–170.
  • Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25 (27): 3778–3786.
  • Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005;3 (10 Suppl 2): S132–S135.
  • Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S108–S112.
  • Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12 (8): 1175–1181.
  • Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, Satomura S. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001;16 (2): 105–111.
  • Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131 (6): 1758–1767.
  • Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125 (1): 89–97.
  • Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37 (5): 1114–1121.
  • Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38 (12): 2170–2176.
  • Taouli B, Krinsky GA. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006;12 (11 Suppl 2): S1–S7.
  • Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S133–S143.
  • Taouli B, Losada M, Holland A, Krinsky G. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S144–S152.
  • Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101 (3): 513–523.
  • Liu WC, Lim JH, Park CK, Kim MJ, Kim SH, Lee SJ, Lee WJ, Lim HK. Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol 2003;13 (7): 1693–1698.
  • Quaia E, Stacul F, Gaiani S, Ricci P, Passariello R, Curzio D, Pozzi Mucelli R. Comparison of diagnostic performance of unenhanced vs SonoVue–enhanced ultrasonography in focal liver lesions characterization. The experience of three Italian centers. Radiol Med (Torino) 2004;108 (1–2): 71–81.
  • Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. AJR Am J Roentgenol 2007;188 (1): 147–153.
  • Murakami T, Takamura M, Kim T, Hori M, Federle MP, Onishi H, Tomoda K, Nakamura H. Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma. Eur J Radiol 2005;54 (2): 246–252.
  • Liu WY, Jin Y, Rong RH, Ta X, Zhu XS. Multi-phase helical CT in diagnosis of early hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2 (1): 73–76.
  • Laghi A, Iannaccone R, Rossi P, Carbone I, Ferrari R, Mangiapane F, Nofroni I, Passariello R. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003;226 (2): 543–549.
  • Li L, Liu LZ, Xie ZM, Mo YX, Zheng L, Ruan CM, Chen L, Wu PH. Multi-phasic CT arterial portography and CT hepatic arteriography improving the accuracy of liver cancer detection. World J Gastroenterol 2004;10 (21): 3118–3121.
  • Kawata S, Murakami T, Kim T, Hori M, Federle MP, Kumano S, Sugihara E, Makino S, Nakamura H, Kudo M. Multidetector CT: diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 2002;179 (1): 61–66.
  • Rizvi S, Camci C, Yong Y, Parker G, Shrago S, Stokes K, Wright H, Sebastian A, Gurakar A. Is post-Lipiodol CT better than i.v. contrast CT scan for early detection of HCC? A single liver transplant center experience. Transplant Proc 2006;38 (9): 2993–2995.
  • Zheng XH, Guan YS, Zhou XP, Huang J, Sun L, Li X, Liu Y. Detection of hypervascular hepatocellular carcinoma: comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT. World J Gastroenterol 2005;11 (2): 200–203.
  • Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J; Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38 (4): 1034–1042.
  • Colagrande S, Centi N, Galdiero R, Ragozzino A. Transient hepatic intensity differences: part 1, those associated with focal lesions. AJR Am J Roentgenol 2007;188 (1): 154–159.
  • Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol 2006;58 (2): 200–216.
  • Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005;237 (2): 520–528.
  • Simon G, Link TM, Wörtler K, Doebereiner F, Schulte-Frohlinde E, Daldrup-Link H, Settles M, Rummeny EJ. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol 2005;15 (5): 895–903.
  • Kwak HS, Lee JM, Kim YK, Lee YH, Kim CS. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol 2005;15 (1): 140–147.
  • Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, Ko D, Kim TS, Cho AE, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med 2005;46 (10): 1753–1759.
  • Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ, Lee KU. The role of 18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12 (11): 1655–1660.
  • Chen YK, Hsieh DS, Liao CS, Bai CH, Su CT, Shen YY, Hsieh JF, Liao AC, Kao CH. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005;25 (6C): 4719–4725.
  • Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4 (3): 361–368.
  • Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, Moutardier V, Farges O, Valla D. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001;35 (2): 254–258.
  • Schotman SN, De Man RA, Stoker J, Zondervan PE, Ijzermans JN. Subcutaneous seeding of hepatocellular carcinoma after percutaneous needle biopsy. Gut 1999;45 (4): 626–627.
  • Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42 (5): 1208–1236.
  • Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH, et al Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89 (2): 259–266.
  • Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnù L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97 (3): 734–744.
  • Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130 (7): 417–422.
  • McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, Dunaway E, Williams J. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32 (4 Pt 1): 842–846.
  • Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000;6 (3): 320–325.
  • Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12 (4 Pt 1): 680–687.
  • El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44 (1): 158–166.
  • Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; Barcelona Clinic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40 (6): 1352–1360.
  • Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141 (2): 181–190.
  • Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23 (11): 1535–1547.
  • Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S179–S188.
  • Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37 (2): 429–442.
  • Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127 (5 Suppl 1): S248–S260.
  • Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229 (6): 790–799.
  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334 (11): 693–699.
  • Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S268–S276.
  • Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33 (6): 1394–1403.
  • Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007;13 (3): 391–399.
  • Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122 (4): 889–896.
  • Fuss M, Salter BJ, Herman TS, Thomas CR Jr. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 2004;127 (5 Suppl 1): S206–S217.
  • Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl 1): S194–S205.
  • Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127 (5 Suppl 1): S189–S193.
  • Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004;13 (12): 1555–1568.
  • Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006;12 (43): 6955–6960.
  • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66 (24): 11851–11858.
  • Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24 (26): 4293–4300.
  • Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25 (18S): LBA1.
  • Marx J. Recruiting the cell's own guardian for cancer therapy. Science 2007;315 (5816): 1211–1213.
  • Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25 (27): 3866–3884.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.